Statistics from Altmetric.com
In 2009, around £73.5million was spent on the lipid-regulating drug ezetimibe in England (plus around another £10million on the combination product simvastatin plus ezetimibe) out of a total primary care prescribing spend of £8.5billion. By comparison, just £10million was spent on the drug in 2004. This increase (mirrored throughout the UK) contrasts with a fall in overall expenditure …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.